Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

Kathleen M. Dungan MD, MPH Advisory Board

Richard E. Pratley MD Associate Editor

See All Experts

featured

Published in Diabetes

Journal Scan / Research · August 17, 2022

Effects of Tofogliflozin and Glimepiride on NAFLD in People With Type 2 Diabetes

Diabetes Care

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Fernando Bril MD

Diabetes Care

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Diabetes Care 2022 Jul 27;[EPub Ahead of Print], Y Takeshita, M Honda, K Harada, Y Kita, N Takata, H Tsujiguchi, T Tanaka, H Goto, Y Nakano, N Iida, K Arai, T Yamashita, E Mizukoshi, H Nakamura, S Kaneko, T Takamura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Effects of Tofogliflozin and Glimepiride on NAFLD in People With Type 2 Diabetes

Additional Info

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Further Reading

Effect of Insulin Type (Ultra-Rapid Vs Rapid Insulin) and Exercise Timing on Postprandial Exercise–Induced Hypoglycaemia Risk in Individuals With Type 1 Diabetes

Gastric Bypass Elicits Persistent Gut Adaptation and Unique Diabetes Remission–Related Metabolic Gene Regulation

Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in People With Diabetes and Advanced Chronic Kidney Disease

Prognostic Significance of Diabetes in Patients With NSCLC Treated With Immune Checkpoint Inhibitors

Real-World Effectiveness of Oral Semaglutide in Adults and Older Individuals With Type 2 Diabetes

Effect of Combined Use of SGLT2 Inhibitors and Pioglitazone on the Risk of MASH in Individuals With Type 2 Diabetes

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Implications of Continuous Ketone Monitoring in Clinical Practice

Characterizing the Effects of Using GLP-1 Receptor–Based Agonists on Body Composition

The SEAD Program Improved Clinical Outcomes in Underserved Young Adults With Type 1 Diabetes

Predicting Hypoglycemia and Hyperglycemia Risks During and After Physical Activity in Adolescents With Type 1 Diabetes

Recently Updated